Terumo Corporation 4543

This article first appeared on GuruFocus. Terumo Corp (TRUMF) recently announced a total dividend of $0.11 per share, with the ex-dividend date set for September 29, 2026. This upcoming distribution consists entirely of a $0.11 per share cash dividend, though the specific payable date has not yet been confirmed by the company.

The global interventional cardiology devices market is forecast to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a 6.4% CAGR. Growth is driven by rising cardiovascular disease, aging populations, demand for minimally invasive procedures, better healthcare access, and advances in stents, imaging and catheter technologies. Plain angioplasty balloons, embolic protection devices, guidewires and hospitals will see strong growth, while Asia Pacific is set to be the fastest-growi

The global vascular access device market is projected to grow from USD 6.27 billion in 2026 to USD 8.68 billion by 2031, at a 6.7% CAGR. Growth is driven by rising cancer, cardiovascular and kidney disease cases, increased IV therapies and advances in safety-engineered, antimicrobial and ultrasound-guided devices. Peripheral devices and drug administration will see strong growth, while clinics and ambulatory care centers gain adoption. Asia Pacific is forecast to record the highest CAGR. Key pla

National Institute for Health and Care Excellence (NICE) guidance supports wider patient access to life-saving liver transplantation through routine adoption of machine perfusion technologies across EnglandOXFORD, United Kingdom and MADISON, N.J., Aug. 21, 2026 (GLOBE NEWSWIRE) -- OrganOx Ltd., a leading organ medical technology company and wholly owned subsidiary of Terumo Corporation, today welcomed NICE guidance supporting routine NHS funding and access to ex-situ machine perfusion technologi

Terumo Corp (TRUMF) posts record Q1 results with revenue up 9% locally and operating profit soaring 60%, driven by robust global demand and boosted by tariff refunds and settlement proceeds.

Disposables lead the product segment, while plasmapheresis holds the largest procedure share. North America dominates the market. Key players include Terumo, Fresenius, Haemonetics, BD and B. Braun. Apheresis Market Apheresis Market Dublin, July 24, 2026 (GLOBE NEWSWIRE) -- The "Apheresis Market by Product, Procedure, Application, Technology, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global apheresis market is projected to grow from USD 3.02 bil

Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.

Terumo (TSE:4543) is back in focus after reporting full year results to March 31, 2026, with sales of ¥1,131,877 million and net income of ¥135,914 million, both higher than a year earlier. See our latest analysis for Terumo. The earnings release has been met with a sharp change in sentiment, with a 24.53% 7 day share price return and a 21.99% 90 day share price return contrasting with a 1 year total shareholder return that declined 9.96%. This suggests short term momentum is building after a...

Terumo Corporation has reported past full-year results for the 12 months to March 31, 2026, with sales rising to ¥1,131.88 billion and net income reaching ¥135.91 billion, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year. The combination of stronger revenue and earnings indicates that Terumo improved its profitability over the period, suggesting that recent operational initiatives and cost controls have been effective. We’ll now...

Japan's regenerative medicine market offers opportunities driven by an aging population, progressive regulations, and demand for novel therapies targeting chronic and cosmetic conditions. Innovations in stem cell and gene-editing technologies, alongside robust R&D investments and clinical collaborations, further bolster growth potential.Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Japan Regenerative Medicine Market - Distribution by Type of Product, Type of Therapeutic Area, End User and Key Ge

The catheter market is poised for significant growth due to rising chronic disease prevalence, increased minimally invasive procedures, and enhanced healthcare access in emerging regions. Opportunities lie in product innovation, particularly in advanced coatings and diagnostic features, and expansion strategies in Asia-Pacific and other developing areas. Catheters Market Catheters Market Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Catheters Market" report has been added to ResearchAndMarkets

Drug-Eluting Stents Market Drug-Eluting Stents Market Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Drug-Eluting Stents Market Report by Coating, Drug, Stent Platform, Generation, Application, End User, and Region ?2026-2034?" has been added to ResearchAndMarkets.com's offering. The global drug-eluting stents market size, valued at USD 9.2 Billion in 2025, is projected to reach USD 14.5 Billion by 2034, growing at a CAGR of 5.03% from 2026 to 2034. This growth is largely driven by the increasi

NORTHAMPTON, MA / ACCESS Newswire / April 15, 2026 / The Healthcare Plastics Recycling Council (HPRC) is pleased to welcome Terumo Corporation, a global medical technology company that develops, manufactures, and distributes medical devices and solutions, ...

Caristo Diagnostics, a University of Oxford spinout and a global leader in AI technology for cardiovascular disease, today announced the appointment of Board Member Stephen M. Deitsch as Chief Executive Officer (CEO), effective immediately.

ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He br

In March 2026, Terumo Corporation filed a shelf registration for up to ¥200 billion in bonds and, a few days earlier, Tata Elxsi announced the opening of the Terumo–Tata Elxsi Offshore Development Center to support Terumo’s cardiac and vascular solutions worldwide. The creation of this dedicated Offshore Development Center highlights Terumo’s push to combine advanced engineering, AI-enabled software, and regional customization to enhance its cardiac and vascular device portfolio and...

Tata Elxsi, a global leader in design and technology services, and Terumo Corporation, a global medical innovation company, today inaugurated the 'Terumo–Tata Elxsi Offshore Development Center'. This dedicated center will support the development of Terumo's cardiac and vascular solutions, strengthening engineering and innovation capabilities while enabling continuous lifecycle support across international markets.

$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs NEW HOPE, Pa.